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evidenced by elevated C-reactive protein and low serum albumin)
has been established as an independent predictor of survival in
patients with metastatic breast cancer. However, the relationship
between these systemic inflammatory markers, clinicopathologi-
cal characteristics and cancer specific survival has not been
established in early breast cancer.
Methods: During the period June 2001–May 2008, patients with
early breast cancer presenting to two hospitals in the West of
Scotland were prospectively included into this study (n = 959).
Preoperative C-reactive protein, albumin and clinico-pathological
data were recorded for each patient. The thresholds for normal C-
reactive protein and albumin were taken as <6 mg/l and >43 g/l
respectively.
Results: The median follow-up of the survivors was 4.1 years.
During this period, 93 patients died of their cancer. On multivar-
iate analysis, tumour size (HR 2.03; 95%CI 1.41–2.91, P < 0.001),
lymph node status (HR 2.23; 95%CI 1.45–3.41, P < 0.001), hormone
receptor status (HR 1.58; 95%CI 1.24–2.00, P < 0.001) and albumin
<43 g/l (HR 1.97; 95%CI 1.28–3.01, P = 0.002) were significant inde-
pendent predictors of cancer-specific survival. Lower serum albu-
min concentrations (<43 g/l) were associated with deprivation
(P = 0.019) and significantly poorer 5-year cancer-specific survival
(85% vs. 92% P = 0.005).
Conclusions: The results of the present study show that lower
preoperative albumin concentrations, but not elevated C-reactive
protein concentrations, predict cancer-specific survival, indepen-
dent of clinico-pathologic status in early breast cancer. Albumin
may be a useful clinical prognostic factor in these patients.
doi:10.1016/j.ejcsup.2010.06.066
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We have investigated the expression pattern of the MCPH1
protein microcephalin and evaluate its prognostic importance in
breast cancer. Microcephalin is a damage response protein
involved in the regulation of BRCA1 and BRCA2 in the homolo-
gous DNA repair pathway. BRCA1 mutations are often associated
with basal-like breast cancer. MCPH1 immunohistochemistry was
performed on 319 breast cancers and correlated with pathology,
survival, ER, PR, HER2, EGFR, CK5/6, CK14 and BRCA1 data.
After performing continuous data analysis mean microcepha-
lin expression decreased with increasing grade, grades 1 and 2 vs.
grade 3 (p < 0.006). Interestingly mean microcephalin expression
was also lower in ER/PR negative (p < 0.001) and triple negative
cancers (p < 0.004). Conversely an association with HER2 positive
cancers was also identified (p < 0.03). No association was identi-
fied with basal markers or BRCA1 cytoplasmic staining.
After dichotomizing the data into low and high microcephalin
expression, reduced expression was identified in 29% (93/319) of
breast cancers. A weak association with low microcephalin
expression was identified with overall survival (OS) p = 0.1 in the
whole patient series. This was increased in ductal carcinomas
alone (HR = 0.6, 95%CI: 0.4–1, p = 0.054). Multivariate analysis of
ductal carcinomas showed that microcephalin, together with
stage, was considered an independent predictor of OS (HR = 0.5,
95%CI: 0.3–0.851, p = 0.01).
Microcephalin expression is reduced in 29% of breast cancers,
particularly in higher grade tumours and is an independent pre-
dictor of OS in ductal carcinomas. Microcephalin may prove to
be a useful biomarker for the identification of aggressive breast
cancers.
doi:10.1016/j.ejcsup.2010.06.067
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Background: Proliferation rates of tumour cells provide prog-
nostic and therapy predictive information. Mitotic index (MI), S-
phase fraction (SPF) and Ki67/MIB-1 are used to assess
proliferation.
Aim: To compare the proliferation assays and explore their
correlation.
Patients and methods: MI, SPF and 5-year follow-up data were
explored for 670 patients from the hospitals of Kalmar County.
MI, Ki67/MIB-1 and 3-year follow-up data for 403 patients from
the Sahlgrenska University Hospital were extracted.
Results: MI and Ki67 were both significantly correlated to early
recurrence, p < 0.001. The optimal correlation between MI and
Ki67 was achieved when both were separated in three groups
with cut off values for Ki67 of 10 and 30%. Spearman r = 0.69,
p < 0.0001. The 39 early distant recurrences were distributed in
the MI group 1–3, group 2–11 and group 3–25 recurrences. Two
pts with Ki67 <10% had distant recurrences, 22 with 10–30% and
15 pts in the group of Ki67 < 30%.
The combination of diploidy and low SPF identified pts with
the lowest and MI 3 those with the highest risk of distant
recurrence.
Conclusion: Mitotic index was superior to Ki67 and SPF to iden-
tify pts with inferior prognosis. The cytometric assay was supe-
rior to identify pts with the best prognosis. There was a
significant correlation between MI and Ki67 when both were
stratified into three groups.
doi:10.1016/j.ejcsup.2010.06.068
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